Literature DB >> 9655741

Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message.

K A Hanson1, F Burns, S D Rybalkin, J W Miller, J Beavo, W R Clarke.   

Abstract

During transitional circulation, the pulmonary vascular bed undergoes a rapid and profound reduction in both tone and vascular smooth-muscle (VSM) content. 3',5'-Guanylate cyclic monophosphate (cGMP) is a crucial mediator in the regulation of pulmonary vascular resistance (PVR) and VSM proliferation. Hydrolysis of cGMP is achieved predominately by cGMP-specific phosphodiesterases (PDEs). Among the cGMP-specific PDEs, PDE5 is quantitatively prevalent in lung tissue. We have investigated the levels of pulmonary PDE5 enzymatic activity, protein, and messenger RNA (mRNA) in ovine and mouse lung during perinatal development. We report that within 1 h following birth, PDE5 activity, protein, and mRNA levels decrease in both species, in a manner that correlates with known decreases in PVR in early transition. However, from 4 to 7 d following birth, a secondary increase in PDE5 activity, protein, and mRNA occurs in both ovine and mouse lung, suggesting a complex regulation of PVR and VSM proliferation in late perinatal development. Our data imply that PDE5 may be an important mediator in the regulation of PVR in normal and possibly in pathologic states, and may ultimately provide a basis for PDE5 inhibitors as a treatment for pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655741     DOI: 10.1164/ajrccm.158.1.9711042

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  17 in total

1.  PBX transcription factors drive pulmonary vascular adaptation to birth.

Authors:  David J McCulley; Mark D Wienhold; Elizabeth A Hines; Timothy A Hacker; Allison Rogers; Ryan J Pewowaruk; Rediet Zewdu; Naomi C Chesler; Licia Selleri; Xin Sun
Journal:  J Clin Invest       Date:  2017-12-18       Impact factor: 14.808

Review 2.  Therapeutic approaches using nitric oxide in infants and children.

Authors:  Robin H Steinhorn
Journal:  Free Radic Biol Med       Date:  2011-01-13       Impact factor: 7.376

3.  Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.

Authors:  Marc Chester; Gregory Seedorf; Pierre Tourneux; Jason Gien; Nancy Tseng; Theresa Grover; Jason Wright; Johannes-Peter Stasch; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-19       Impact factor: 5.464

Review 4.  Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension.

Authors:  Kathryn N Farrow; Robin H Steinhorn
Journal:  Handb Exp Pharmacol       Date:  2011

5.  SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension.

Authors:  Kathryn N Farrow; Satyan Lakshminrusimha; Lyubov Czech; Beezly S Groh; Sylvia F Gugino; Jonathan M Davis; James A Russell; Robin H Steinhorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-04-16       Impact factor: 5.464

6.  Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs.

Authors:  Robert C Dukarm; Robin H Steinhorn; James A Russell; Satyan Lakshminrusimha; Daniel Swartz; James J Cummings
Journal:  J Appl Physiol (1985)       Date:  2005-08-25

7.  Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells.

Authors:  Kathryn N Farrow; Beezly S Groh; Paul T Schumacker; Satyan Lakshminrusimha; Lyubov Czech; Sylvia F Gugino; James A Russell; Robin H Steinhorn
Journal:  Circ Res       Date:  2007-11-08       Impact factor: 17.367

8.  Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.

Authors:  Peter M Mourani; Marci K Sontag; D Dunbar Ivy; Steven H Abman
Journal:  J Pediatr       Date:  2008-10-31       Impact factor: 4.406

9.  Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.

Authors:  H A Toque; C E Teixeira; F B M Priviero; R P Morganti; E Antunes; G De Nucci
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

10.  Immunohistochemical localisation of PDE5 in rat lung during pre- and postnatal development.

Authors:  Angela Scipioni; Mauro Giorgi; Valeria Nuccetelli; Stefania Stefanini
Journal:  J Biomed Biotechnol       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.